Compare AbbVie Inc (ABBV) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? AbbVie Inc trades at $248.54 (market cap $441.94B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.09. The key difference: AbbVie Inc pays a 2.77% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | LQD | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | — |
52-Week High | $263.58 | $112.91 |
52-Week Low | $197.38 | $105.96 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
